GLPG
Galapagos NV (GLPG)
Healthcare • NASDAQ • $27.730.00%
- Symbol
- GLPG
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $27.73
- Daily Change
- 0.00%
- Market Cap
- $1.86B
- Trailing P/E
- 4.88
- Forward P/E
- -17.34
- 52W High
- $37.78
- 52W Low
- $24.74
- Analyst Target
- $28.46
- Dividend Yield
- N/A
- Beta
- 0.12
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Company websiteResearch GLPG on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.